Lipella Pharmaceuticals Inc SEC Filings

LIPO OTC

Welcome to our dedicated page for Lipella Pharmaceuticals SEC filings (Ticker: LIPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Decoding a biotech 10-K packed with clinical data and patent jargon is tough—especially when Lipella Pharmaceuticals’ pipeline spans liposomal platforms, Oral Lichen Planus trials, and hemorrhagic cystitis breakthroughs. If you have ever searched “Lipella Pharmaceuticals SEC filings explained simply” or wondered which Form 4s flagged fresh insider buys, you know the challenge.

Stock Titan’s AI-powered analysis turns that complexity into clarity. You’ll get real-time alerts the moment a “Lipella Pharmaceuticals insider trading Form 4 transactions” post to EDGAR, concise summaries of every quarterly earnings report 10-Q filing, and plain-English highlights from 8-K material events. Our platform pinpoints where R&D expense shifts, clinical-trial results, or new patents appear—so you don’t have to scan hundreds of pages.

Whether you’re tracking dilution risk through the proxy statement executive compensation tables, comparing LP-310 trial spend quarter over quarter, or confirming a “Lipella Pharmaceuticals annual report 10-K simplified” revenue breakout, all filings live here with AI context. Monitor “Lipella Pharmaceuticals Form 4 insider transactions real-time,” study segment notes, or export data for models—every document from 10-K and 10-Q to S-8 is updated instantly and explained in language you can act on.

06/25/2025 03:14 PM

Filing

[8-K] LIPELLA PHARMS INC Reports Material Event

Rhea-AI Summary

Lipella Pharmaceuticals (LIPO) filed an 8-K announcing its delisting from the Nasdaq Capital Market. The company released a stockholder letter from CEO Jonathan Kaufman addressing the delisting and outlining plans to relist on a national exchange. The filing includes a press release and stockholder letter as exhibits 99.1 and 99.2.

As an emerging growth company, Lipella provided standard forward-looking statements cautioning that actual outcomes may differ from expectations regarding product candidate development and relisting efforts.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

14.62%

[8-K] Lipella Pharmaceuticals Inc. Reports Material Event

Rhea-AI Summary

Lipella Pharmaceuticals Inc. ("LIPO") has been formally delisted from the Nasdaq Capital Market. On 20 June 2025 the company received a Nasdaq Hearings Panel letter, dated 17 June 2025, exercising discretionary authority under Listing Rule 5100 to delist the company’s common stock. The Panel cited two rule violations that arose from private placements conducted between December 2024 and March 2025: (i) failure to secure prior shareholder approval for issuances exceeding 20 % of outstanding shares below the minimum price (Rule 5635(d)), and (ii) actions that disparately reduced or restricted existing shareholders’ voting rights (Rule 5640).

Trading in LIPO shares was suspended at the market open on 20 June 2025. The company expects to file Form 25 with the SEC to formally remove its listing. As of the suspension date, the common stock now trades on the OTC Markets Group’s Pink Market under the existing ticker "LIPO".

The 8-K also furnishes a press release (Exhibit 99.1) announcing the delisting. Management emphasises that forward-looking statements in the filing involve significant risk and that the company is evaluating all market alternatives for future listing; however, no concrete remediation plan or timeline is provided.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-30.08%

FAQ

What is the current stock price of Lipella Pharmaceuticals (LIPO)?

The current stock price of Lipella Pharmaceuticals (LIPO) is $0.9 as of June 27, 2025.

What is the market cap of Lipella Pharmaceuticals (LIPO)?

The market cap of Lipella Pharmaceuticals (LIPO) is approximately 11.8M.

What is the primary focus of Lipella Pharmaceuticals Inc?

Lipella Pharmaceuticals is focused on developing new therapies by reformulating active agents from existing generic drugs. The company targets serious diseases with significant unmet needs, emphasizing conditions where no approved treatments currently exist.

How does Lipella generate value with its business model?

The company uses a strategy of repurposing established drug molecules and optimizing them through advanced liposomal drug delivery techniques. Revenue generation is primarily driven by clinical trial programs, intellectual property development, and potential licensing or partnership agreements.

What are Lipella’s key product candidates?

Lipella’s core pipeline includes candidates such as LP-10 and LP-310, which are designed for conditions like hemorrhagic cystitis and Oral Lichen Planus. Additionally, investigational programs like LP-20 demonstrate the company’s adaptability in both therapeutic and diagnostic applications.

How is Lipella addressing conditions with unmet medical needs?

By focusing on diseases that lack approved treatments, such as Oral Lichen Planus and hemorrhagic cystitis, Lipella targets areas with significant clinical demand. Its innovative formulations aim to provide localized therapeutic effects, offering potential improvements over existing palliative treatments.

What differentiates Lipella's liposomal drug delivery platform?

Lipella’s delivery system utilizes metastable liposomes to ensure targeted application of therapeutic agents, thereby reducing systemic exposure and side effects. This advanced formulation technology supports greater efficacy and safety across multiple therapeutic areas.

What is the significance of Lipella's clinical trials?

The ongoing Phase 2a trials demonstrate the company’s commitment to clinical rigor and transparency. These trials evaluate the safety, tolerability, and efficacy of their drug candidates in addressing specific conditions, thereby reinforcing Lipella’s focus on solving unmet clinical needs.

How does Lipella protect its innovations?

Lipella maintains a strong intellectual property portfolio through strategic patent filings, including patents on its proprietary liposomal delivery technology. This protection helps secure market exclusivity for its lead clinical assets and supports its long-term research efforts.

How does Lipella Pharmaceuticals differ from other biotech companies?

Unlike companies that focus solely on new drug discovery, Lipella’s model centers on reformulating existing generic drugs using novel delivery platforms. This approach allows them to quickly address unmet clinical needs while ensuring that therapies are both effective and safe.